Results 221 to 230 of about 603,898 (307)

Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.

JAMA Cardiol
Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD, SEQUOIA-HCM Investigators.   +23 more
europepmc   +1 more source

Effects of Obesity and Sex on Ventilatory Constraints during a Cardiopulmonary Exercise Test in Children. [PDF]

Med Sci Sports Exerc
Bhammar DM, Nusekabel CW, Wilhite DP, Daulat S, Liu Y, Glover RIS, Babb TG.   +6 more
europepmc   +1 more source

Exercise Stress Testing for Ischmic Heart Disease in AMHTS

, 1990
松田 典子, 伊藤 妙, 北川 信博, 太田 壽城, 水野 嘉子   +4 more
openalex   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Exercise limitation in hypertrophic cardiomyopathy: combined stress echocardiography and cardiopulmonary exercise test. [PDF]

ESC Heart Fail
Erez Y, Ghantous E, Shetrit A, Zamanzadeh RS, Zahler D, Granot Y, Sapir OR, Laufer Perl M, Banai S, Topilsky Y, Havakuk O.   +10 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Comparing the Physiological Responses to the 6-Minute Walk Test, Timed Up and Go Test, and Treadmill Cardiopulmonary Exercise Test. [PDF]

Rehabil Res Pract
Alves ES, Bellet RN, Sharma P, Balmain BN, Aitken C, Doering T, Orola L, Green A, Paim T, O'Connor F, Morris NR.   +10 more
europepmc   +1 more source

Exercise Testing [PDF]

European Heart Journal, 1996
openaire   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Exercise Testing

, 2007
Bernard R. Chaitman, Masarrath J. Moinuddin, Junko Sano   +2 more
openaire   +2 more sources